TP53 and acute myeloid leukemia: Taken together, these data suggest that the delayed CAR T-cell-mediated killing of MOLM13-TP53−/− AML cells, and therefore prolonged antigen exposure to CAR T-cells likely contributes to the observed sustained activation, increased exhaustion, and consequently, lower therapeutic efficacy against TP53-mutant AML cell lines in vitro.